Clinical Trials by Drug

147 recruiting trials (FDA-approved across 4 cancer types, 8 distinct labels)

Broadest ADC approval portfolio in oncology — the most-developed HER2-targeted antibody-drug conjugate (Daiichi Sankyo with AstraZeneca global partnership since Mar 2019). Humanized anti-HER2 IgG1 (trastuzumab backbone) + cleavable tetrapeptide linker + deruxtecan (DXd, exatecan-derivative topoisomerase I inhibitor) at high DAR ~8. Same deruxtecan platform as Datroway (anti-TROP2) + patritumab deruxtecan (anti-HER3) — completes the Daiichi DXd trio. 8 distinct FDA approvals: HER2+ mBC 3L+ (DESTINY-Breast01 Dec 2019, replaced by DB-03 Apr 2022 2L+ vs T-DM1, OS HR 0.64); HER2+ gastric/GEJ 2L+ (DESTINY-Gastric01 Jan 2021, confirmed by DB-Gastric02 Phase 3); HER2-low mBC (DESTINY-Breast04 Aug 2022 — landmark Phase 3 doubling eligible breast ADC population, OS HR 0.64); HER2-mutant NSCLC (DESTINY-Lung02 Aug 2022); tumor-agnostic HER2 IHC 3+ (Apr 2024 DESTINY-PanTumor02); HER2-ultralow mBC IHC 0 with membrane staining (DESTINY-Breast06 Aug 2024); and 1L HER2+ mBC + pertuzumab (DESTINY-Breast09, Dec 15, 2025 — first new 1L HER2+ mBC standard in a decade, 44% reduction in PFS/death vs THP, median PFS 40.7 vs 26.9 months). FDA boxed warning: interstitial lung disease / pneumonitis (~10-15% incidence, 1-3% fatal, deruxtecan-platform class effect shared with Datroway). Recruiting Phase 3 pipeline: DESTINY-Endometrial01 (NCT06989112 T-DXd + rilvegostomig); HER2+ BTC T-DXd + rilvegostomig (NCT06467357 + NCT06764875); 1L HER2+ gastric T-DXd + chemo + pembro + trastuzumab (NCT06731478); HER2+ BMETs SRT (NCT06088056); HER2-low BMETs + bev (NCT07150208); intrathecal/Ommaya T-DXd for leptomeningeal disease (NCT07134153). Cross-platform sequencing: TRADE DXd Phase 2 (NCT06533826) head-to-head Dato-DXd vs T-DXd in ADC-refractory breast. Class: HER2 antibody-drug conjugate, deruxtecan platform.

23 recruiting trials

HER3 ADC (Daiichi Sankyo / Merck) — first HER3-targeted ADC in Phase 3. HERTHENA-Breast03 registrational (NCT07060807); EGFR-mutant NSCLC post-osimertinib; NRG1 fusion; pediatric R/R solid tumors.

18 recruiting trials

DLL3 × CD3 BiTE — SCLC, NEC, NEPC, MCC, brain tumors. FDA-approved 2024.

25 recruiting trials

First-in-class BCMA × CD3 bispecific T-cell engager (Janssen / J&J) — multiple myeloma. FDA accelerated approval Oct 2022 for 4+ prior line RRMM. MajesTEC-4 post-ASCT maintenance Phase 3 (NCT05243797), MajesTEC-7 Tec-DR vs DRd in newly diagnosed transplant-ineligible MM (NCT05552222), the Tal-Tec arm of NCT06208150 in earlier-line RRMM, and the head-to-head Phase 3 vs the BCMA × GPRC5D dual-bispecific JNJ-79635322 (NCT07518186). REVIVE high-risk smoldering MM + 6 AL amyloidosis trials. Defining safety signal: infections + hypogammaglobulinemia.

17 recruiting trials

First-in-class GPRC5D × CD3 bispecific T-cell engager (Janssen / J&J) — multiple myeloma. FDA accelerated approval Aug 2023 for 4+ prior line RRMM. Phase 3 (NCT06208150) Tal-P / Tal-Tec vs EPd / PVd in 1L+ RRMM post anti-CD38 + lenalidomide; Phase 3 Tal-DR vs DRd in transplant-ineligible newly diagnosed MM; post-BCMA CAR-T sequencing; subcutaneous administration. Distinct side-effect profile (dysgeusia, skin / nail changes).

11 recruiting trials (FDA-approved)

Class: gp100 × CD3 bispecific T-cell engager (ImmTAC). First-in-class TCR-based bispecific (Immunocore) — engineered soluble HLA-A*02:01-restricted TCR fused to anti-CD3 scFv; targets intracellular gp100 peptide on HLA-A*02:01 (differentiates from antibody-based BiTEs which target cell-surface antigens). FDA-approved Jan 25, 2022 as the only therapy for HLA-A*02:01+ metastatic uveal melanoma — IMCgp100-202 Phase 3 OS HR 0.51 (median 21.7 vs 16.0 mo) despite ORR ~9% (the landmark ORR/OS dissociation that established the "biological response" concept). ATOM Phase 3 (NCT06246149 adjuvant ocular melanoma) + TEBE-AM Phase 3 (NCT05549297 HLA-A*02:01+ cutaneous melanoma post-IO) + NCT06942442 Phase 2 clear cell sarcoma (first non-melanoma ImmTAC cross-cancer extension) + neoadjuvant + PHP combinations. Defining safety: CRS (~89%, almost all Grade 1-2) + skin reactions; intra-patient dose escalation (20-30-68 mcg).

62 recruiting trials

PD-1 × VEGF bispecific (Akeso / Summit) — approved in China. HARMONi-6 Plenary at ASCO 2026 (May 31). FDA PDUFA Nov 14, 2026.

12 recruiting trials

PD-1 × TIGIT bispecific (AstraZeneca) — investigational. 10 Phase 3 across NSCLC (TROPION-Lung10, ARTEMIDELung04), biliary (DESTINY-BTC01, AB02), HER2+ gastric (D702AC00001), HCC (ARTEMIDE-HCC01), endometrial (DESTINY-Endometrial01).

88 recruiting trials

PD-1 × CTLA-4 bispecific (Akeso) — approved in China. 10 Phase 3 in gastric, cervical, HCC, NSCLC, NPC, CRC.

50 recruiting trials (FDA-approved)

First FDA-approved TROP2 ADC — hRS7 humanized anti-TROP2 IgG1 antibody + hydrolyzable CL2A linker + SN-38 (irinotecan metabolite, topoisomerase I inhibitor) payload at high DAR ~7.6, with documented bystander effect on TROP2-low neighbors (Gilead Sciences via the Sep 2020 Immunomedics acquisition). 2 active FDA indications: metastatic TNBC 2L+ (ASCENT Phase 3 full approval Apr 2021, replacing the Apr 2020 IMMU-132-01 accelerated approval) and HR+/HER2-low or HER2-negative locally advanced or metastatic breast cancer 2L+ after endocrine therapy (TROPiCS-02, Feb 2023). A third indication (urothelial cancer) was voluntarily withdrawn by Gilead in Apr 2025 after TROPiCS-04 missed its primary OS endpoint. First Phase 3 of a TROP2 ADC in SCLC (NCT06801834) + neoadjuvant TNBC + cross-cancer signals (mCRC, HNSCC, thyroid, mesothelioma, GBM, cervical, ovarian). Class: TROP2 antibody-drug conjugate.

16 recruiting trials (FDA-approved)

Second FDA-approved TROP2 ADC (after Trodelvy) and second Daiichi Sankyo deruxtecan-platform brand alongside Enhertu (T-DXd, anti-HER2) and patritumab deruxtecan (HER3-DXd). Humanized IgG1 anti-TROP2 antibody (datopotamab) + cleavable tetrapeptide linker + deruxtecan (DXd, exatecan-derivative topoisomerase I inhibitor) at DAR ~4 (AstraZeneca + Daiichi Sankyo). 2 active FDA indications: HR+/HER2-low (IHC 1+/2+ ISH-) OR HER2-ultralow (IHC 0 with membrane staining) metastatic breast cancer after prior endocrine therapy and chemo (TROPION-Breast01 Phase 3 regular approval Jan 17, 2025) and EGFR-mutant locally advanced or metastatic NSCLC after prior EGFR-TKI and platinum chemotherapy (TROPION-Lung05 Phase 2 single-arm, accelerated approval Jun 23, 2025). The HER2-ultralow inclusion is unique among approved TROP2 ADCs. Honest framing: TROPION-Lung01 Phase 3 narrowly missed OS primary endpoint vs docetaxel in overall NSCLC; EGFR-mutant label carved from TROPION-Lung05 + subgroup analyses. FDA boxed warning for interstitial lung disease (deruxtecan-platform class effect); distinctive ocular toxicity (dry eye, keratitis — baseline ophthalmology required) and stomatitis (TROPION-DM mouthwash prophylaxis trial). TRADE DXd Phase 2 head-to-head vs T-DXd in ADC-refractory breast; DATO-BASE in breast brain mets; TROPION-Breast05 in HER2 IHC 0; TROPION-Lung10 1L osimertinib + Dato-DXd EGFR-mutant; TROPION-Lung08 1L Dato-DXd + rilvegostomig. Class: TROP2 antibody-drug conjugate, deruxtecan-platform.

48 recruiting trials (FDA-approved)

First FDA-approved PSMA-targeted radioligand therapy and the prototype of the theranostic class — PSMA-617 small-molecule ligand (glutamate-urea-based) conjugated via a DOTA chelator to the beta-emitting radionuclide lutetium-177 (~6.7 day half-life, ~2 mm beta path length), developed by Novartis via Advanced Accelerator Applications (AAA). 2 active FDA indications in PSMA-positive mCRPC: post-NHA + post-taxane (VISION Phase 3 / NCT03511664, initial approval Mar 23, 2022) and post-NHA pre-chemotherapy (PSMAfore Phase 3 / NCT04689828, label expansion 2025). PSMA-PET imaging required upfront for eligibility (Locametz / Illuccix / 68Ga-PSMA-11 or Pylarify / 18F-DCFPyL). Distinctive xerostomia / dry-eye / cytopenia side-effect profile from on-target salivary, lacrimal, and bone-marrow radiation. Phase 3 expansion into earlier-disease settings (PEACE6 mHSPC poor-PSA-responder, oligometastatic), AAA817 (225Ac-PSMA-617) alpha-emitter post-Pluvicto sequencing, PSMA-low strategies (LPS-Boost, vorinostat priming), cabazitaxel head-to-head (NCT06738303). Class: PSMA-targeted radioligand therapy.

7 recruiting trials (FDA-approved)

KRAS G12C-selective oral covalent inhibitor (Bristol Myers Squibb via Mirati Therapeutics). 2 FDA accelerated approvals: KRAS G12C NSCLC 2L+ monotherapy (KRYSTAL-1, Dec 2022) and KRAS G12C metastatic CRC + cetuximab after fluoropyrimidine/oxaliplatin/irinotecan (KRYSTAL-1 + KRYSTAL-10, Jun 2024). Differentiator vs sotorasib: documented CNS penetration and reported intracranial activity in NSCLC brain metastases (NCT06248606 SRS combo). Registrational 1L NSCLC KRYSTAL-12 Phase 3 NCT06875310 + Phase 1b/2 CRC + cetuximab + cemiplimab NCT06412198. Class: KRAS G12C-selective covalent inhibitor.

15 recruiting trials (RAS(ON) franchise)

First-in-class pan-RAS(ON) multi-selective inhibitor (Revolution Medicines). 3 Phase 3: RASolute 302 (1L metastatic PDAC), RASolute 304 (adjuvant resected PDAC), RASolve 301 (RAS-mutated NSCLC). Plus companion compounds elironrasib (G12C), RMC-9805 (G12D), RMC-5127 (G12V).

6 recruiting trials

PEGylated arginine deiminase — HCC Phase 3, leiomyosarcoma Phase 3 (ARGSARC), AVPC, GBM, NASH.

56 recruiting trials (FDA-approved)

First FDA-approved PARP inhibitor (Dec 2014) — AstraZeneca/Merck. 4 FDA indications, 7 approvals: ovarian (SOLO-1, PAOLA-1, SOLO-2), HER2-negative gBRCA breast (OlympiA adjuvant, OlympiAD metastatic), HRR-mutated mCRPC (PROfound, PROpel + abiraterone), gBRCA pancreatic maintenance (POLO). Targets BRCA1/2-mutated and HRD+ tumors via synthetic lethality. Class: PARP inhibitor.

24 recruiting trials (FDA-approved)

Oral once-daily PARP1/2 inhibitor — GSK via Tesaro acquisition (Dec 2018). Broadest PARP indication of any FDA-approved PARPi: PRIMA 1L ovarian maintenance regardless of BRCA/HRD status (Apr 2020 — the only PARPi without a 1L ovarian biomarker requirement) and NOVA recurrent ovarian maintenance regardless of BRCA (Mar 2017). QUADRA late-line ovarian voluntarily withdrawn (2023). BBB-penetrant pharmacology drives Phase 3 NCT06388733 niraparib vs temozolomide in MGMT-unmethylated GBM — first PARP Phase 3 in glioma. Class: PARP inhibitor.

33 recruiting trials (FDA-approved)

First FDA-approved CDK4/6 inhibitor (Feb 2015 accelerated, Mar 2017 full approval) — Pfizer. 3 FDA settings in HR+/HER2- advanced breast cancer: 1L + letrozole (PALOMA-1 / PALOMA-2), 2L + fulvestrant (PALOMA-3, Feb 2016), male breast cancer (Apr 2019). NOT approved adjuvant — PALLAS + PENELOPE-B failed (unlike Kisqali NATALEE and Verzenio monarchE). Targets the CDK4/6-cyclin D-Rb axis at the G1/S checkpoint. Class: CDK4/6 inhibitor.

~100 recruiting trials (FDA-approved across 4 cancer types)

Oral once-daily multikinase inhibitor targeting VEGFR1-3, FGFR1-4, PDGFR-alpha, KIT, and RET — uniquely covers all four FGFR receptors at clinically-achievable concentrations, the basis for its FGFR-driven tumor activity beyond classical anti-angiogenesis (Eisai with Merck pembrolizumab-combination global partnership since Mar 2018). 5 FDA approvals across 4 cancer types: differentiated thyroid cancer (May 2015 SELECT Phase 3 vs placebo, PFS HR 0.21), advanced RCC + everolimus (May 2016 Study 205 Phase 2), 1L unresectable hepatocellular carcinoma (Aug 2018 REFLECT Phase 3 non-inferiority vs sorafenib, OS HR 0.92, ORR 40.6% vs 12.4% by mRECIST), 1L advanced RCC + pembrolizumab (Aug 2021 CLEAR Phase 3 vs sunitinib, OS HR 0.66, ORR 71%), advanced endometrial cancer + pembrolizumab (Sep 2019 accelerated / Jul 2021 regular all-comers, KEYNOTE-775 / Study 309 Phase 3 OS HR 0.62 pMMR, 0.68 all-comers). Honest framing required: REFLECT was non-inferiority, not superiority; IMbrave150 demonstrated atezo + bev OS-superior to sorafenib (median OS 19.2 vs 13.4 months), so atezo + bev is the preferred 1L HCC for eligible patients — Lenvima is the 1L alternative for atezo + bev-ineligible patients (active autoimmune disease, untreated esophageal varices, severe portal hypertension, bevacizumab contraindications). Defining toxicity: hypertension Grade 3+ ~40% (highest of any approved multikinase TKI — BP must be <150/90 before initiation, monitored weekly × 8 weeks). Recruiting pipeline dominated by HCC + Chinese PD-1 + locoregional (TACE/HAIC/SBRT/I-125) combinations; Phase 3 endpoints: NCT05608200 lenvatinib+sintilimab+TACE; NCT05985798 sintilimab+bev+TACE vs lenvatinib+TACE; NCT05823311 lenvatinib+tislelizumab+GPLET; NCT06089382 sintilimab+lenvatinib adjuvant; NCT07475026 neoadjuvant tislelizumab+lenvatinib resectable HCC. Notable platform combos: NCT06034977 ADI-PEG 20+lenvatinib HCC; NCT06984718 cadonilimab+lenvatinib 2L HCC. Cross-cancer: TNBC neoadjuvant pembro+lenva (NCT04427293), ER+/HER2- breast lenva+letrozole vs fulvestrant (NCT05181033), platinum-sensitive ovarian (NCT04519151), well-differentiated G3 NET (NCT05746208), 11q13-amp solid tumors (NCT07417501), bone sarcoma (NCT05617859, NCT07619950). Class: oral multikinase VEGFR / FGFR / RET / KIT inhibitor.

6 recruiting trials

Moderna + Merck personalized neoantigen mRNA cancer vaccine — custom-manufactured mRNA encoding ~34 patient-specific neoantigens. 3 Phase 3 adjuvant resected NSCLC (INTerpath-002, INTerpath-009, INTerpath-014). Phase 2 advanced melanoma (INTerpath-012), metastatic squamous NSCLC (INTerpath-013), high-risk NMIBC + BCG (INTerpath-011). Almost always combined with pembrolizumab. FDA Breakthrough Therapy Designation (adjuvant melanoma).